CORT - Earnings call transcript Q3 2024 | Corcept Therapeutics Incorporated

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and thank you for standing by. Welcome to the Corcept Therapeutics Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Atabak Mokari, Chief Financial Officer. Please go ahead.

Atabak Mokari

everyone. Hello, thank us. and for you afternoon, joining Good Today, results providing for a press a our financial release announcing the update. we issued corporate third quarter and A at copy is available corcept.com.

our our will being is A risks Statements statements Events uncertainties or are Form are forward-looking statements and replay them at based the that all when those than which update financial implied. other duty to tab release additional SEC. Today's available press recorded. materially be on are described described on available for be Investors in intention of complete with expressed documents the release or uncertainties, information. the results to we publicly Please in on those XX-Q, Our These quarterly forward-looking are plans reports on may call during are be file the risks report statements. Form that statements our will annual to of press historical XX-Q call any affect today's disclaim website. cause available Past this We statements forward-looking such and might expectations website. and our and of subject to XX-K SEC's in actual and Form which fact our and the results refer from different

increase million, Our to quarter of year. revenue quarter in last of XX% compared an third was $XXX.X XXXX third of the the

year. quarter million and growth third third $XX.X have the million revenue continue million our of the was $XX.X the revenue $XXX in compared to our income to to to quarter expect Net We $XXX increased guidance million. prior XXXX in

Charlie? acquired net our stock to restricted stock were our XX Our call vesting pursuant repurchase Officer. at now XX. employees Charlie cash Chief third exercise our over common compared to Robb, the at of June grants. I by million Corcept million and $XXX.X stock to options the of $XX.X quarter investments million in the $XXX.X of September and Business the stock will program, net turn We

Gary Robb

quarter. to much Thanks, Atabak. this don't have report I

and As to complete. year, marketing know, against Briefing We are of generic to in at documents March is Appeals. next oral trial least would In unable many January of appealed last step we XXXX of we court and of next is XXXX and from for Korlym as court to oral our approval available The The could matter version the it violation be until the ruled of the Teva the of Circuit next product. Pharmaceuticals of us. the market to Circuit issue argument. year schedule early December decision a FDA would Federal website, prevail, a its the in patents in our at that in product Court schedule argument government's in you sued lose as Federal decision the PACER Teva patents. the If expiration stop the quarter. of

in that patent correct call are As Belanoff, to eager the Joe? Federal expertise agree. I'll and the its with position turn Chief advance before, Circuit appeal. that our Executive Officer. over law believe we We strongly I've said is deep our this will now to Joe

Joseph K. Belanoff

GRADIENT Corcept. by results new from this thank clear drug in path and The is the GRACE accelerating. Phase year-end. Cushing which and for will us very Charlie, submit syndrome, everyone, studies is for Physician hypercortisolism afternoon. time exciting joining III relacorilant's of This you, we a you, understanding at our Thank and application awareness

physicians will cancer company. in More Cushing of in with high patients and new number that difficult-to-treat trial assumed. are prevalent Korlym patients the previously CATALYST transform trials number these and quarter aware of Success prescribers is patients We in data the much with both in diabetes will our the with IV endeavors third Our another syndrome quarter receiving as Phase now ovarian this generate was than and more will Korlym. with the ALS. hypercortisolism treatment ended

is treating a they refined expertise prescribed, many the developed As more Korlym optimum physicians screening have achieve critical years and in and benefit. patients. When patients result, infrastructure we are over and role plays many a and helping

improvements and selective glucose Perhaps Korlym the as story well our weight in relacorilant. important, Our Patients and control, in advancement not experienced body business made thriving. the is related signs The used the vaginal by GRACE we and to endometrial other GRADIENT even have cause that and studies of Cushing of its bleeding, hypokalemia, do insufficiency. is recently in events more hypertrophy, Cushing substantial complicated. progress can adverse as of in some modulator, meaningful symptoms be prolongation hypertension, syndrome, was composition QT proprietary and cortisol treat tolerated serious adrenal not well caused medications very Relacorilant syndrome. particular, other

pivotal of weight, score X.XX. those compared cognition, to a Cushing mass, patients GRACE which endpoint, patients taking with Cushing XX placebo. Xx III more of withdrawal relacorilant placebo enter recall, which open-label taking other GRACE, In received weeks. Patients primary the met XX for X.XX relacorilant means was were phase our improvements the half randomized odds compared patients GRACE response life trial waist withdrawal half the for pressure measures. lean in of XXX and phase, those both, Patients quality and patients were meaningful statistically significant of in phase, that met GRACE Phase the hypertension, taking or phase hyperglycemia either and placebo, to with p-value study's relacorilant likely clinically continue endpoint prespecified blood As of hyperglycemia, received pressure control. blood circumference, to syndrome double-blind to relacorilant trial's important basis opportunity exhibited maintain The maintenance In of given muscle open-label ratio, taking its the in the of to which receive you hypertension, ratio the trial's is randomized and of who relacorilant's is for An odds weeks. the primary NDA. clinical improvements X.XX

who cortisol Patients also in it the only received meaningful those weeks with compared and those relacorilant's continue while received who placebo released p-value are substantially the In received and type whose decline, our adrenal often placebo-adjusted compared who adrenal second deciliter, with received millimeters patients with significantly include randomized in glucose significant. Patients the relacorilant was outcomes or take with in NDA, own, X cortisol III and by required significant results GRADIENT, placebo-controlled experience relacorilant experience of syndrome, that of an therapy. we a the experienced whether Phase weeks. An In mercury patients in with is from of higher weeks. of the to own. compared tolerated systolic was or trial Notably, an and was weight a who who relacorilant X.X%, those pressure Patients glucose XX their not risk on received to were common received in data compared Cushing's GRADIENT. blood Patients hypertension statistically nausea, who p-value GRACE. compared hypertension placebo meaningful X.X at a in and statistically experienced double-blind, worsening how who most improvements of a of for maintained did to withdrawal patients improvement powerful received placebo metabolism less to to extremities removes randomized, weight who improvements caused the required rescue X in Today, with while significant XX secreting relacorilant Patients pressure the of range the who clinically poor following studies, and These symptoms. These well XX composition who systolic difference broad but p-value in on at meaningful other and placebo medication, loss hyperglycemia, in weeks stand received pain tumor moderate is start trial's health hemoglobin outcomes our of syndrome placebo ACTH they body but withdrawal while to in to had relacorilant improvement improvements had with their experienced fatigue. those to significant adenoma endpoints. would, pressure XX gradient XX-week composition placebo and it. X.X efficacy of relacorilant back, or received the X.XXXX hypercortisolism statistically fastening open-label adverse received by improvement. XX safety, of improvement received hyperplasia. of of endpoint whose to hypertension, due hyperglycemia, baseline, their patient per The we both received statistically their medical provide do with addition, important to their in relacorilant placebo-adjusted this blood our found further observed in an p-value weight milligrams of of relacorilant body rapid symptoms their the and an in X.XXX. compared XXX not who in clinically are in compared nonsignificant mercury phase evidence of weight as phase, X.XXX rapid a X.XXX improvements of hypertension Cushing The study evidence medications. hypercortisolism significant a placebo hypertension of AXc reduction and with millimeters improvement a primary providing a NDA given death. GRADIENT's Patients at treated baseline systolic both hyperglycemia consistent study events and in premature rescue secondary blood cortisol of confirming those exhibited Patients were surgery not. improvements a with mild relacorilant and what will worsened placebo during baseline, in in and feature GRACE clinically support who who activity, GRADIENT at body patients kilograms in patients X.X of

As expected, prolongation. no or QT hypertrophy of of related there bleeding, cases insufficiency endometrial and were no of instances its vaginal hypokalemia, cases no adrenal relacorilant-induced

positive can health study, look relacorilant's medications used in work All of patients new for treat efficacy patients taking further physician to now with Cushing supported great arise have and the in continue with patients promise improvement syndrome. events drug adverse rates GRADIENT currently Concurrent advance a hypercortisolism. The consequences syndrome. awareness of safety patients increase seen understanding to the the we our application, these by in Cushing to with result and global and serious on

who The more prevalence patients than was annual June. in Scientific in found the first X that CATALYST was prevalence addition to hypercortisolism. Our there were large in hypercortisolism from demonstrated assumed enrolled evidence X patients Phase CATALYST, more those produced medications had hypercortisolism. IV common the to results of in Diabetes CATALYST the even than was This with X using They patients with care. Hypercortisolism presented in this in Of to with far X,XXX patient particularly who, have potent higher advance recognized. Association's X/X field. are are to were American is already Sessions their rate clearly difficult-to-treat diabetes, to for or a of have disease, hypertension. in significantly previously in diagnosed study More study cardiovascular group manage help patients patients were than their diabetes of has implications more found the

portion hemoglobin AXc between of it, The placebo. receive primary In second are study randomized is the hypercortisolism The patients these with Korlym groups. or the in endpoint to is CATALYST either ongoing. reduction

of results study this the year. end the expect of portion We by the of

medication study, plus know, on cancer either with been with we pivotal ovarian basis a as relacorilant. different have resistant prescribed randomized nab-paclitaxel platinum a or cortisol ROSELLA studying our receive women are activity. a to disease relacorilant by types In platinum-resistant nab-paclitaxel, one-to-one you to mediated treatment women As also cancer for often of XXX

years after our nab-paclitaxel, Our design will Phase activity. ROSELLA's cortisol effects controlled women II the XX% to those relacorilant in alone. II received exhibited intermittently, trial. nab-paclitaxel significant relacorilant successful to the duration took closely the the tracks by of before, expectation live tumors received took effect anti-apoptotic survival improvement arm. of versus patients study the in response relacorilant after the longer a is of received and the Phase nab-paclitaxel day intermittent the and the of relacorilant ovarian blunting XX% the of day who comparator X progression-free in resensitize monotherapy. alive only design start group of than who compared day trial, were who that who the statistically Women also In chemotherapy they group

received relacorilant the those no compared who burden who women experienced Importantly, alone. received to nab-paclitaxel effect side additional nab-paclitaxel plus

by We expect We complete. progression to primary is of to anticipate this ROSELLA study's in survival replicate events the progression-free enough having ROSELLA analyze results. Enrollment end these endpoint, the year.

appreciate ENGOT collaboration ROSELLA their and have in enthusiasm with We group, are Gynecological stand-alone relacorilant the we as it. States and ROSELLA so conducting can leading the established express Europe, deeply in Gynecologic prompt ovarian or explore Trials, a the women In European clinicians also a us or treatment Oncology to the anticipation from in Oncology after GOG, to other receptor. outcome, Network and for United of of solid and Group, we of a the results successful glucocorticoid conclusion of to stages oncology earlier from bring that the move will who swiftly Positive benefit can division relacorilant cancer support. tumors

exploring this clinicians resurgent block that enzalutamide, escape modulation's switched other treated evaluating we receptor stimulation mechanisms their cortisol to why androgen cancer a with immunotherapy. to tumor potential with reason disease. to be growth. Leading activity deprivation in with researchers androgen hypothesize of patients chemotherapy, are stimulate and prostate tumor eventually addition its and cortisol antagonist, In modulation to in X experience cortisol resensitize to Deprived major stimulation, of to a Cortisol can androgen activity action combination therapy is widely route. thought tumors prescribed academic

collaborators Our had of randomized Chicago with in currently the initial Phase prostatectomy. are early-stage an these II University placebo-controlled patients plus before relacorilant at of enzalutamide a patients prostate have enrolling cancer trial

Another Because suppresses as enhance immunotherapy. it with checkpoint cortisol such Adding the role of intended therapies effectiveness to to in modulator their immunotherapies may system. of cancer effectiveness. stimulate modulation system, the immune blunt immune cortisol may inhibitors combination a potential is cortisol the

and cancer. Following Ib to tumor combination of evaluating our trial cancer, further modulation stages immunotherapies of the with adrenal understand role we cortisol advanced next Phase steps in types in other in earlier are

of selective modulators X,XXX cortisol library more properties. pharmacodynamic has than research Our distinct with developed a team

tissue potent Some activity are some are types, in more many modulating tissue-specific. across cortisol

Some less models, some oncologic are very potent in so.

Some cross barrier, some the don't. blood-brain

getting is dazucorilant. the One scientists at of created into the have compounds is effective our brain that highly

a We into and clinical of reduced motor dazucorilant in have mouse model and ALS. commonly muscular data on atrophy performance used based improved neuroinflammation advanced studies compelling showing

have sites XXX DAZALS The measure weeks. of milligrams a impact on is II to on is with XX ongoing receive Our XXX basis double-blind randomized functional Phase ALS primary for dazucorilant rating of at been double-blind, revised Canada. Europe, a patients score, trial patients. milligrams United ALS placebo-controlled and scale placebo the clinical in States the XXX either validated on of has endpoint dazucorilant, ALS the or performance randomized

of liver cortisol modulation may an to receive activity implicated expect of a of metabolic the the that for afflicts data patients States. the the in treatment We the by is disorder end has United as serious effective year. MASH, dysfunction-associated because in been Cortisol initial millions steatohepatitis progression MASH serve both development and disease.

found triglycerides orally dose-finding fat Our insulin XX% in serum a metabolic of Phase patients who measures of and XXX improvements weeks experienced enzymes, lipid XX miricorilant key a in reduction and as received liver Ib twice resistance, study just markers for fibrosis and such that LDL. milligrams and liver week

was patients the arise miricorilant effects Importantly, with very for MASH. of in also which commonly none being well-tolerated GI side treated

MONARCH are In the is receive twice to either XXX for these biopsy-confirmed with biopsy-confirmed randomized weekly results. weeks. MASH secondary encouraging patients Our randomized miricorilant is to placebo-controlled X The IIb X:X enrolling first, this study resolution fibrosis aims endpoint Phase on MONARCH expand XX and double-blind, placebo fat milligrams XXX for in endpoints. or key reduction MASH improvement, of with cohort liver primary cohorts.

XXX XX Corcept. reduction incredibly twice fat. This cohort, In either milligrams time or Patients primary weeks has the by be is planned followed will for second XX for in a this liver randomized an X:X twice weekly in of the to patients exciting endpoint weeks, miricorilant a The milligrams enrollment with MASH. X weekly is presumed at this receive for cohort miricorilant cohort also placebo XX of XXX whole of weeks.

expect trial Cushing studies in at treatment and we've treatment we DAZALS Positive our assumed. GRACE results understands do. ovarian patients end that transformative study distinct more a to far superior the ALS. be for Cushing GRADIENT study The as from cancer demonstrate will and, Corcept for results The the benefit patients this there patients from strong. is of with clear prevalence study business results from patients serve. Every it was previously our year, well we than that syndrome. receive syndrome make developed By in commercial with data we our work for syndrome of trial pivotal are Our CATALYST ROSELLA in more these lead the CATALYST Cushing to in importance great the important, employee results as our and company with the

and make cortisol We difference. Operator, where are driven modulation quickly the support as as other to with Cushing proceed can, syndrome can to now patients effectively a let's disorders and we questions.

Operator

Our question line Piper from of Sandler. first the Amsellem Instructions] [Operator of David comes

David Amsellem

So couple data. the just GRADIENT have a on

to to think trying understand I'm this. better guess about how I First,

be pressure So differences versus significant. versus given should specifically versus able with you placebo, baseline? difference absence changed endpoint, data only I I that confidence I approval But NDA? one, active gives question understand blood have what regarding role for approval? the be number placebo, then to GRADIENT that needed part one of And will drug hand communication the FDA number was you your the you the the but statistically then question is, just not here able in with Has not of get last to the of that, guess gradient guess file you interpret two, is given GRADIENT the how released is that baseline. on my not backdrop? the And the that here separation in

Joseph K. Belanoff

Yes. you, David. Thank

Chief I like to Guyer. all questions. you of And is think just Bill Bill understood to I'd Development our those pass I over first, Officer.

he I your question answer previous You've calls, data very think specifically. on can heard him and

William Guyer

asked. you've I address -- that your I for question. you, thank I David, can questions all think hopefully can

based at data very data. as not it's out, just with important you pointed we're confident NDA but you to GRADIENT most the GRADIENT GRADIENT the the is look that, submitting remember data, an had upon thing the So when

as us we is Our the X III don't largest study. a about Study which supportive and but much, will extension X total NDA and study for II another today, our I hundreds long-term NDA we studies, study, pivotal Cushing's patients. as is GRADIENT ], include studies, our gives GRACE Phase XXX [ talk of a have Phase of study our Altogether, this and as III study package will Phase syndrome,

this So other done no has the far. large with FDA company of going a that thus to package,

GRACE, of And going FDA. met the Now be GRADIENT always always primary GRACE and be from endpoint was inception we agreement its that's study, our supportive with our for was to designed and our pivotal GRACE. to

look improvements with of X me in GRADIENT the let weight, GRACE all because including symptoms, in blood blood that hyperglycemia few. Now improvements probably as our of path see signs clinically just a hypertension we trials pressure, examples. When Cushing's look And are me an is remind name trial, from syndrome, syndrome and Cushing at of just to and symptoms GRADIENT, those many at signs a and it the or or signs results significant the supports you NDA successful symptoms. to a glucose, trial and XX -- you even together, all let more and we

Now continues see through comes that week pressure all when our immediate X in XX. it out and we to week blood at blood studies pressure, drop in of an starts

statistically we endpoints fasting hemoglobin see with as when blood response those. significant HOMA that, syndrome, see had improvements look coagulation even glucose, look factors, improvement we also part to significant greater we overt and significant all to improvements AUC that when we as But mentioned. even diabetes, we addition produces relacorilant. at higher you see because resistance AXc, data, statistical see as coagulation tell also other In and all we like well patients we Joe relacorilant AXcs and IR look all a an at And as factors the hemoglobin for in AUC glucose of favoring insulin clinically insulin of in and have in improvements factors, of in when hyperglycemia I'll at the

belly weight to fat saw losing Patients compositions body what see. when are fat area, improvements we Joe the and is the bad in body which As is well, DEXA in which visceral we as area, significant do from the wanted mentioned, we had scans.

altogether, speaks Cushing's of improvement So syndrome to broad study. this the the GRADIENT from

trial. important is prolongation. as of or that, especially to cases I've differentiate it seen no helps profile, and addition new product, because because safety any vaginal no GRACE safety insufficiency, look it's QT Phase you of with relacorilant relacorilant well safety consistent In really reiterate saw it no in at And II, got with in signals We hypokalemia no what bleeding, that no and the see and were from when the to of known drug-induced cases of other of profile evidence the as reported confirms we hypertrophy adrenal this Korlym. interval endometrial without GRADIENT

to All GRACE. is and of supportive saw what of similar this that we of in

other me a I patients come back Phase trial that let is study, NDA also come forward. XXX Now into study III trial. and over Study also feel or with This takes moving of come the why from from positive a II this confident enroll to study roll GRACE Phase and GRADIENT that our

their patients see and and years, will over people we evaluate switch to on progression randomized who to able for data will relacorilant trial, this now have be some be have been remained we'll this from well. over as placebo were see we able who to so who X relacorilant on and And

blood studies unblinded, improve that month highly tell at response this continues supportive out and of And both of data. study shows is diastolic because what seen can you continues to we hypertension GRADIENT out and the look years. in clinically pressure improvements in statistically that it Now systolic I and significant evaluate at X, significant and X our we've and all I'm will

have successful to we coming relacorilant. see the of when look studies, will for we That at a path totality evidence happen positive in NDA all So a that of you the these we from weeks. believe

Joseph K. Belanoff

Bill. you, Thank

please. Next question,

Operator

line Matt the question Kaplan. comes next of Our from

Matthew Kaplan

a CATALYST Korlym just can the Thanks on with seeing terms impact Cushing's. bit prevalence for question if up then results very with you're was screenings That the already. to the And going are identify for during helpful talk little the respect patients to you're additional showing you Gradient. results that the results, of clearing of in on quarter, an the about seeing initial

Joseph K. Belanoff

Yes, much that I that. best Go question. prepared for Matt. the And Maduck, the Sean. understand Sean Thanks ahead, our Endocrinology division, I to President question. answer very of think is

Sean Maduck

is thanks we to some roll yes, the and for Hi, in some that results. impact to starting question. say Matt, the from practices, are mean, see CATALYST yes, answer for I full to takes And short to guidelines it's I the those see going and into time it of sort will those though results take some time effect.

our that on but the volume full And the XXXX. will touch to effect it, Joe see So last it's couple that multiple obviously, have What I the prevalent recent more his and that beyond. comments, highlighted in was that number. enforced X once highlighted the is been number I later to with seen once we and X growth is in We're of thought. ultra-rare And into is that bigger. the we mentioned expectation wanted XXXX even most is in And in have that of There's -- catalyst considered longer though started of curve on front specifically at XXXX this One, and of is hypercortisolism really why. that growth. CATALYST just FDA wanted the fact, getting touch part tremendous it guidance it that's years than studies in no disease. early an the

they're of shift. shifting. at patients, routine more is prevalence, them looking to this the become we're just Because these across behavior. finding groups. we're And screening beginning that going that again, But and prevalence. They're we're physician the screening different seeing for that So and paradigm multiple time, confident over a of there's is more more far

with increased syndrome, this great So but the increased and is and be in is walked in shows adrenal and expect through have is the substantial through I safety term. going as Korlym not across multiple the near cause Bill better. to screening, all not hypokalemia. in it long Cushing's of and just and relacorilant benefit. and not we to the Joe with that It product, we mean his efficacy volume other does in QT market. products that even progesterone Korlym. does symptoms comments, recognition It more separates signs walked a not prevalent all it and cause be the growth significant the does cause effects term really It see has from the It off-target doesn't which prolongation, deficiency

So growth we we're because where the business billion we next fact be of this and on believe track because X see of this a years. $X in going, to a

Joseph K. Belanoff

Sean. you, Thank Thank you.

Next question, please.

Operator

of comes next the Swayampakula Our question Ramakanth H.C. of Wainwright. from line

Swayampakula Ramakanth

This from question A study. the on quick ROSELLA H.C. RK is Wainwright.

stating year. expect prepared will the the Joe, by that remarks, analysis that in So all you you you were you end the that have for need events the of

by to the the So year? you of the of enough and the even do having have my to get just enough data? release you events question is, end would time analysis the Or do think point will you

Joseph K. Belanoff

going answer to me just you second. pass Bill your for a Bill let question to I'm back generally.

less events your the best a studies occur period As XX-week we a you for do study because blind determined have you're that. bit for results, opposed break and studies a to where, number you to of have And instance, waiting double-blind -- a with oncology other little calculation. XX-week you and of are course, and have you done

I'll ahead. Now Bill, out when course in But go and specifics, kind oncology specificity to for to will result the for oncology par is give lack -- studies. give understand that a of you Bill an please back from the study you just of but read

William Guyer

Yes.

agree more a but color, little that. completely add I I'll So bit with

look a on see II. So differential in that response resistant combination OS is other key we drug what's at a saw Phase relacorilant when of and any response. effect platinum of ovarian or from nab-paclitaxel, cancer the PFS thing duration you that plus is And in that differentiates driving benefit probably it we that duration

benefit plus out, the for alone. model were especially X at relacorilant you in II of longer were who nab-pac women who Phase versus if women that greatest saw where So nab-pac the is longer, trial year amount the living we living Xx

X is Xx that we're a larger. Now study replicating to that in

And so to the of it that women come are just progressing. does down number

to cross living we that women endpoint on prepared goes, soon year this as hope data the shows plus end soon next talk announce this even on a at relacorilant that it track possible. And and it it of and the then conference we as longer and that I my as that that are the we team can year. Now publicly analyze of as are to once events, that number and cross longer about we're But nab-paclitaxel. data by present to see analyze

Joseph K. Belanoff

release our But information event. important analyses RK. is soon are as obviously that done, we very will as a This

about what just We it's to you day hear You'll going can't yet. tell be it.

Next question, please.

Operator

comes question Joon next of the Our Lee. line from

Joon Lee

of is characterization GRADIENT pivotal. GRACE a supportive FDA? while Your as Is that the seems study view the by be shared to

Joseph K. Belanoff

I'd pass provide affairs, can over to And you like useful color Yes. I regulatory our some really handles who very all Charlie of Robb, to and to you. think

Gary Robb

And this we a Hi, think Yes. of one isn't art that thing on and which is that have as where guess The -- yes. to Bill safety you gave listeners published efficacy. I you confirmatory the as do Joon. of we're some a I FDA's syndrome pointed with sponsor any sure team data a the with guidance the studied, our form in really just have we Cushing's but patients than mind. what's underscore to single answer I not made approved and in to the the where study, I'm company there. perspective dark maybe all the relacorilant position view, go more we GRACE FDA, well in Bill conversations the out with understand, but just the from have any has to FDA what mean the other well-controlled our a mean from strong it demonstrate treatments wanted may clinical And clear to in. has person there's as a the of and is present with arguments evidence have along out, I is sufficient GRACE, drug's good

It's across the GRACE, entire symptoms. really who data. tremendous our consistent study as the our got of to easy relacorilant amount as been So have we to argument signs and GRADIENT, a patients have and to Phase simple that. from to range syndrome better an remarkably FDA. Cushing's It's II present receive that And of now to findings extension

Joon Lee

to And last the within It And seems already you pre-NDA you're have with planning was the interaction when FDA? the like it. submit with the FDA? weeks. have NDA meeting Got a

So the just that already had you've if conversation with curious FDA.

Gary Robb

to Well, FDA. our program, our so But and we can appreciate, in. talked of I about don't FDA no with impediments NDA plenty to particulars mean, I mean say you'll the that our we've programs, I on foresee this about comment of the getting I the all absolutely interactions

Joon Lee

I it. please. the to endpoint just more, [indiscernible]. the that Got hyperglycemia One wanted from separate if placebo? Is clarify

Joseph K. Belanoff

who The answer separate with the said. those from endpoints just Joon let placebo? who is treated hyperglycemia yes. patients Did on were that me repeat were with But question treated the Bill, relacorilant the

William Guyer

Yes, they were got hyperglycemia all favoring higher all we statistically AXc. significantly even relacorilant different better got for and endpoints endpoints as those

diabetes. overt who hit So sicker we were and it hit for patients for patients, with also all it we

Joseph K. Belanoff

at much those this you, to thank all time just a have followed helped. is repeat, a patients and everybody, no This of exciting Well, opportunity is happen, when tuning -- things been in. Corcept. help time, for really long an than previously for we us there's larger starting to are group for more really who we I'll

results So next you this you. talking very we're the really forward and about sharing to look for next quarter. very, you and Thank excited to

Operator

Thank you. This the Thank session. conclude participation program. for you conference. This in concludes question-and-answer the your does today's

now You may disconnect.

Corcept Therapeutics (CORT) 30 Oct 242024 Q3 Earnings call transcript